Printer Friendly

XOMA AND CENTOCOR ANNOUNCE SETTLEMENT OF ALL OUTSTANDING LITIGATION AND DISPUTES

 XOMA AND CENTOCOR ANNOUNCE SETTLEMENT
 OF ALL OUTSTANDING LITIGATION AND DISPUTES
 BERKELEY, Calif. and MALVERN, Pa., July 29 /PRNewswire/ -- XOMA Corp. (NASDAQ: XOMA) and Centocor Inc. (NASDAQ: CNTO) announced today an agreement to settle all outstanding litigation and disputes worldwide regarding each company's products, patents and patent applications related to anti-endotoxin monoclonal antibodies.
 The agreement covers the XOMA v. Centocor litigation in the U.S. District Court for the Northern District of California and pending appeals, a proceeding initiated at the U.S. International Trade Commission, and the Centocor v. XOMA lawsuit filed in the U.S. District Court for the District of Delaware.
 Centocor has agreed to pay royalties for U.S. sales, if any, of its monoclonal antibody HA-1A, and the companies have agreed to forego all future litigation and administrative proceedings regarding each other's patents and patent applications related to anti-endotoxin monoclonal antibodies.
 XOMA Corp. is a leading company in the development of therapeutic products using monoclonal antibody and recombinant DNA technologies.
 -0- 7/29/92
 /CONTACT: Carol D. DeGuzman of XOMA, 510-644-1170/
 (XOMA CNTO) CO: XOMA Corp.; Centocor Inc. ST: California; Pennsylvania; Delaware IN: MTC SU:


TS-DG -- SF001 -- 4427 07/29/92 08:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 29, 1992
Words:199
Previous Article:K-TRON INTERNATIONAL REPORTS HIGHER SECOND QUARTER AND FIRST HALF RESULTS
Next Article:FORD CREDIT ANNOUNCES RECORD SECOND-QUARTER EARNINGS
Topics:


Related Articles
XOMA VICTORY IN PATENT SUIT SUSTAINED
XOMA REPORTS 1992 SECOND QUARTER FINANCIAL RESULTS
XOMA ANNOUNCES YEAR-END FINANCIAL RESULTS
XOMA REPORTS SECOND QUARTER FINANCIAL RESULTS
XOMA REPORTS THIRD QUARTER FINANCIAL RESULTS
XOMA CORP. REPORTS 1994 SECOND QUARTER FINANCIAL RESULTS
Wechsler Harwood Commences Class Action Suit Against XOMA, Ltd. On Behalf of Shareholders of (XOMA).
MorphoSys and XOMA cross-license antibody technologies.
Biosite to engineer around XOMA patent.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters